Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinaseinhibitor, in combination with riluzole for the treatment of ALS-associatedTDP-43 proteinopathy
TTBK1 and CK1 inhibitors restore TDP-43 pathology and avoid disease propagation in lymphoblast from Alzheimer’s disease patients
Neurodegenerative disease treatments are evolving rapidly, combining current therapies with innovative approaches. Discover the latest advances, including Molefy’s research, and explore effective strategies to improve patient outcomes.
Avoid cell-to-cell disease transmission in ALS patient-based cellular model
Efficacy in transgenic TDP-43 mouse model and in ALS patient-based cellular model
Synthesis and first biological profile of the inhibitors
